Genentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced that the Phase III IMvigor010 study evaluating Tecentriq atezolizumab as an adjuvant after surgery monotherapy treatment did not meet its primary endpoint of diseasefree surviva...
↧